Definium Therapeutics (DFTX) Profit After Tax (2021 - 2026)

Definium Therapeutics (DFTX) has reported Profit After Tax for 6 consecutive years, with -$77.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 231.09% year-over-year to -$77.4 million; the TTM figure through Mar 2026 stood at -$237.8 million (down 208.13% YoY), while the FY2025 annual figure was -$183.8 million, down 69.86% from the prior year.
• Profit After Tax retreated to -$77.4 million in Q1 2026 per DFTX's latest filing, from -$50.6 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$4.9 million in Q4 2022 and bottomed at -$77.4 million in Q1 2026.
• Historically, Profit After Tax has averaged -$30.7 million across 5 years, with a median of -$24.3 million in 2023.
• Annual changes were most pronounced in 2024 — Profit After Tax jumped 80.08% — and 2025, when it slumped 629.71%.
• Definium Therapeutics' Profit After Tax stood at -$4.9 million in 2022, then sank by 395.57% to -$24.3 million in 2023, then plunged by 41.02% to -$34.3 million in 2024, then plunged by 47.73% to -$50.6 million in 2025, then tumbled by 52.83% to -$77.4 million in 2026.
• Business Quant data shows DFTX's Profit After Tax at -$77.4 million in Q1 2026, -$50.6 million in Q4 2025, and -$67.1 million in Q3 2025.